FOLH1 and prostate cancer: Recognized for its ability to target the transmembrane protein PSMA, predominantly expressed in prostate cancer cells, this modality facilitates enhanced radiotracer uptake, thereby enabling superior lesion visualization compared to its conventional counterparts [5].